Fortrea Holdings Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anshul Thakral
- Full Time Employees
- 15,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 Moore Drive Durham NC United States of America 27709
- IPO Date
- Jun 20, 2023
- CIK
- 0001965040
- Website
- fortrea.com
- Similar Companies
- Business
- Fortrea Holdings Inc. (Nasdaq: FTRE) is a leading global contract research organization (CRO) that provides comprehensive clinical development solutions to biopharmaceutical, biotechnology, and medical device companies worldwide. The company offers Phase I-IV clinical trial management; clinical pharmacology services, including first-in-human and exploratory studies; drug development consulting; regulatory guidance; pharmacovigilance; medical writing; data management and biostatistics; patient recruitment; site management; and specialized expertise in oncology, rare diseases, central nervous system disorders, neurodegenerative conditions, and cell and gene therapies. Fortrea delivers these services through flexible models comprising full-service outsourcing (FSO), functional service provider (FSP), and hybrid structures, supported by clinical research units in the U.S. and U.K., cGMP pharmacies, and operations across 90 countries. Incorporated in 2023 following its spin-off from Labcorp in July 2023, Fortrea traces its origins to 1968 through predecessors including Covance and Corning Lab Services, and is headquartered at 8 Moore Drive in Durham, North Carolina. In June 2024, Fortrea completed the divestiture of its Endpoint Clinical (interactive response technology and clinical supply chain solutions) and Fortrea Patient Access (patient access services) businesses to Arsenal Capital Partners, enabling a sharpened focus as a pure-play clinical CRO. Most recently, in 2025, Fortrea announced a strategic collaboration with SCTbio to integrate clinical development with cGMP manufacturing for cell therapy innovators, alongside recognition as a leader in pharmacovigilance operations per the PEAK Matrix Assessment 2025.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea to Attend Jefferies Global Healthcare Conference
Fortrea to Attend Jefferies Global Healthcare Conference
Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates
Fortrea Reports First Quarter 2026 Results
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
SG Americas Securities LLC Raises Stock Holdings in Fortrea Holdings Inc. $FTRE
Assenagon Asset Management S.A. Lowers Stock Holdings in Fortrea Holdings Inc. $FTRE
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fortrea Holdings Inc. $FTRE Shares Sold by Citigroup Inc.
Allianz SE Buys Shares of 48,000 Fortrea Holdings Inc. $FTRE
Fortrea Holdings Inc. (FTRE) Q4 2025 Earnings Call Transcript
Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Fortrea Holdings Inc. (NASDAQ:FTRE) Receives Average Rating of “Hold” from Analysts
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services